Global burden of CVD: focus on secondary prevention of cardiovascular disease
Despite encouraging advances in prevention and treatment of atherothrombosis,
cardiovascular disease (CVD) remains a major cause of deaths and disability worldwide …
cardiovascular disease (CVD) remains a major cause of deaths and disability worldwide …
Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity
Most nations of the world are undergoing rapid and dramatic population ageing, which
presents great socio‐economic challenges, as well as opportunities, for individuals, families …
presents great socio‐economic challenges, as well as opportunities, for individuals, families …
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of …
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …
is recommended in the guidelines, thus completing the loop between clinical research …
The burden of cardiovascular disease in low-and middle-income countries: epidemiology and management
ADK Bowry, J Lewey, SB Dugani… - Canadian Journal of …, 2015 - Elsevier
Cardiovascular disease (CVD) is the second leading cause of mortality worldwide,
accounting for 17 million deaths in 2013. More than 80% of these cases were in low-and …
accounting for 17 million deaths in 2013. More than 80% of these cases were in low-and …
[PDF][PDF] 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Podstawą uaktualnień dotyczących postępowania u pacjentów z zawałem serca z
uniesieniem odcinka ST (STEMI) powinny być rzetelne dowody, pochodzące w miarę …
uniesieniem odcinka ST (STEMI) powinny być rzetelne dowody, pochodzące w miarę …
Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
E Bahiru, AN De Cates, MRB Farr… - Cochrane Database …, 2017 - cochranelibrary.com
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death
and disability worldwide, yet ASCVD risk factor control and secondary prevention rates …
and disability worldwide, yet ASCVD risk factor control and secondary prevention rates …
Current state and future perspective of cardiovascular medicines derived from natural products
C Zhao, S Li, J Zhang, Y Huang, L Zhang… - Pharmacology & …, 2020 - Elsevier
The contribution of natural products (NPs) to cardiovascular medicine has been extensively
documented, and many have been used for centuries. Cardiovascular disease (CVD) is the …
documented, and many have been used for centuries. Cardiovascular disease (CVD) is the …
Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review
R Jahangiri, A Rezapour, R Malekzadeh… - PLoS …, 2022 - journals.plos.org
Background A significant proportion of cardiovascular disease (CVD) morbidity and mortality
could be prevented via the population-based and cost-effective interventions. A fixed-dose …
could be prevented via the population-based and cost-effective interventions. A fixed-dose …
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial
GL Bakris, RR Townsend, JM Flack, S Brar… - Journal of the American …, 2015 - jacc.org
Background: Results of the SYMPLICITY HTN-3 (Renal Denervation in Patients With
Uncontrolled Hypertension) trial confirmed the safety but not the efficacy of renal …
Uncontrolled Hypertension) trial confirmed the safety but not the efficacy of renal …
Procedural results and safety of common interventional procedures in congenital heart disease: initial report from the National Cardiovascular Data Registry
JW Moore, RN Vincent, RH Beekman, L Benson… - Journal of the American …, 2014 - jacc.org
Abstract Background: The National Cardiovascular Data Registry (NCDR) launched the
IMPACT (Improving Pediatric and Adult Congenital Treatment) Registry in 2010. By 2013, its …
IMPACT (Improving Pediatric and Adult Congenital Treatment) Registry in 2010. By 2013, its …